Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DERAIL-LVV: Dapagliflozin and Bosentan in Large Vessel Vasculitis
NCT06887062Phase 2Recruiting
- Sponsor
- University of Edinburgh
- Start
- Mar 2025
- Primary completion
- Jul 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of bosentan and dapagliflozin in large-vessel vasculitis (LVV) (2 arms), sponsored by University of Edinburgh. Primary endpoint: Change in forearm blood flow at 6 weeks. Started Mar 2025; status: recruiting.
02
Drugs
bosentandapagliflozin
03
Conditions
large-vessel vasculitis (LVV)
Beyond the preview
Go deeper on NCT06887062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06887062.